Brokerages expect that Leap Therapeutics Inc (NASDAQ:LPTX) will announce ($0.77) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Leap Therapeutics’ earnings. The firm is expected to report its next earnings results on Monday, February 26th.
On average, analysts expect that Leap Therapeutics will report full year earnings of ($3.63) per share for the current year, with EPS estimates ranging from ($3.73) to ($3.53). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.61) per share, with EPS estimates ranging from ($3.13) to ($2.08). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Leap Therapeutics.
Separately, Zacks Investment Research upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Tuesday, January 23rd.
An institutional investor recently bought a new position in Leap Therapeutics stock. Sabby Management LLC acquired a new position in shares of Leap Therapeutics Inc (NASDAQ:LPTX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned 0.72% of Leap Therapeutics at the end of the most recent reporting period. 1.33% of the stock is currently owned by institutional investors.
Leap Therapeutics (NASDAQ:LPTX) opened at $6.54 on Thursday. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $9.44.
WARNING: “Brokerages Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 Earnings Per Share” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/22/brokerages-anticipate-leap-therapeutics-inc-lptx-to-post-0-77-earnings-per-share.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.